Susquehanna International Group
TSHA icon

Susquehanna International Group’s Taysha Gene Therapies TSHA Stock Holding History

Susquehanna International Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.6K Sell
11,100
-74,400
-87% -$346K ﹤0.01% 12637
2025
Q4 		$470K Buy
+85,500
New +$415K ﹤0.01% 8931
2024
Q4 		– Sell
-10,700
Closed -$21.5K – 13247
2024
Q3 		$21.5K Sell
10,700
-11,700
-52% -$25.7K ﹤0.01% 11617
2024
Q2 		$50.2K Buy
+22,400
New +$65.2K ﹤0.01% 11410
2024
Q1 		– Sell
-32,800
Closed -$58.1K – 13347
2023
Q4 		$58.1K Sell
32,800
-2,500
-7% -$4.98K ﹤0.01% 11654
2023
Q3 		$112K Buy
+35,300
New +$65.9K ﹤0.01% 10829
2023
Q1 		– Sell
-12,700
Closed -$28.7K – 13514
2022
Q4 		$28.7K Buy
+12,700
New +$25.7K ﹤0.01% 11637

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's TSHA Position: Q1 2026 in Review

Susquehanna International Group reduced its Taysha Gene Therapies (TSHA) stake by 6.9% in Q1 2026, selling an estimated $40.4K and leaving 116,297 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #9568.

Susquehanna International Group first reported a position in TSHA in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.76M in Q1 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Susquehanna International Group held 116,297 shares of Taysha Gene Therapies worth $520K as of Q1 2026.
  • Susquehanna International Group sold 8,678 Taysha Gene Therapies shares in Q1 2026, an estimated $40.4K.
  • Taysha Gene Therapies made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9568 holding.
  • Susquehanna International Group first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 14 quarters since.
  • Susquehanna International Group's Taysha Gene Therapies position peaked at $3.76M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.